Defining the Optimal Duration of Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Time for a Personalized Approach?

Despite recent advances, pancreatic ductal adenocarcinoma (PDAC) continues to be associated with dismal outcomes, with a cure evading most patients. While historic treatment for PDAC has been surgical resection followed by 6 months of adjuvant therapy, there has been a recent shift toward neoadjuvan...

Descripción completa

Detalles Bibliográficos
Autores principales: Puleo, Amanda, Malla, Midhun, Boone, Brian A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144367/
https://www.ncbi.nlm.nih.gov/pubmed/37078929
http://dx.doi.org/10.1097/MPA.0000000000002147

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144367/
https://www.ncbi.nlm.nih.gov/pubmed/37078929
http://dx.doi.org/10.1097/MPA.0000000000002147

Ejemplares similares